{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:17:46Z","timestamp":1793049466079,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are rare autoimmune disorders. Their true prevalence in Germany is unknown and can only be estimated from heterogeneous international data. Assuming 1\u20133 cases per 100,000 people for each disease suggests several thousand affected individuals nationwide, yet the German Neuromyelitis Optica Study Group (NEMOS) registry currently holds records of only about 1,300 patients seen in specialised centres. Numbers and care structures outside such facilities remain largely unknown. This survey aimed to assess the current state of NMOSD and MOGAD care in Germany, identify gaps, and inform future care strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An online questionnaire aimed at neurologists and neuropaediatricians was distributed via NEMOS, the German Neurological Society (DGN), the Professional Association of German Neurologists (BVDN), and the German Network for Research on Autoimmune Encephalitis (GENERATE) from March to May 2025. Questions addressed care structures, diagnostics, coding, treatment, guideline use, and practitioners\u2019 needs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 104 physicians from all German federal states participated. Half worked in university hospitals, the remainder in other clinics and outpatient settings. Most were specialised in neuroimmunology (70.2%). Many reported an increase in patient numbers for NMOSD (55.8%) and MOGAD (77.4%). Diagnostic practices revealed significant inconsistencies: almost half of the respondents were unaware of their referral laboratory\u2019s antibody assays, and ELISA remained in use despite clear recommendations for cell-based assays. ICD-10 coding varied widely. Off-label rituximab was most frequently used for first-line therapy of AQP4-antibody-positive NMOSD (69.6%), compared to satralizumab (57.1%), ravulizumab (55.4%) and inebilizumab (50.0%). AQP4-antibody-negative NMOSD was mainly treated with rituximab (87.0%). Also in MOGAD, rituximab was frequently used (by 58.9%), yet paediatricians preferred glucocorticoids and intravenous immunoglobulins. 69.6% initiated treatment for MOGAD after the first attack. Notably, 41.8% of physicians reported untreated NMOSD and 64.6% untreated MOGAD patients. Most respondents relied on national guidelines; 43.2% expressed a need for further education and patient information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings highlight substantial heterogeneity in the diagnosis and treatment of NMOSD and MOGAD in Germany with potential implications for patient outcomes. This underscores the need for harmonised procedures and targeted educational resources to improve diagnostic reliability, treatment equity, and overall quality of care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42466-026-00503-6","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:02:16Z","timestamp":1781884936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unmet needs in the care of patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody associated disease: insights from Germany"],"prefix":"10.1186","volume":"8","author":[{"given":"Katrin","family":"Giglhuber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Zappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Kleiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya","family":"Ayzenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Berthele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Neuromyelitis Optica Study Group (NEMOS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"503_CR1","unstructured":"Orphanet an online rare disease and orphan drug database. Copyright, INSERM 1999. Accessed 17 January 2026. https:\/\/orpha.net"},{"key":"503_CR2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fneur.2020.00501","volume":"11","author":"JY Hor","year":"2020","unstructured":"Hor, J. Y., Asgari, N., Nakashima, I., Broadley, S. A., Leite, M. I., Kissani, N., et al. (2020). Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Frontiers In Neurology, 11, 501. https:\/\/doi.org\/10.3389\/fneur.2020.00501","journal-title":"Frontiers In Neurology"},{"key":"503_CR3","doi-asserted-by":"publisher","first-page":"1260358","DOI":"10.3389\/fneur.2023.1260358","volume":"14","author":"JY Hor","year":"2023","unstructured":"Hor, J. Y., & Fujihara, K. (2023). Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide. Frontiers In Neurology, 14, 1260358. https:\/\/doi.org\/10.3389\/fneur.2023.1260358","journal-title":"Frontiers In Neurology"},{"issue":"2","key":"503_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1212\/wnl.0000000000011153","volume":"96","author":"V Papp","year":"2021","unstructured":"Papp, V., Magyari, M., Aktas, O., Berger, T., Broadley, S. A., Cabre, P., et al. (2021). Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review. Neurology, 96(2), 59\u201377. https:\/\/doi.org\/10.1212\/wnl.0000000000011153","journal-title":"Neurology"},{"issue":"3","key":"503_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell, B., Bennett, J. L., Marignier, R., Kim, H. J., Brilot, F., Flanagan, E. P., et al. (2023). Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. The Lancet Neurology, 22(3), 268\u2013282. https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8","journal-title":"The Lancet Neurology"},{"issue":"4","key":"503_CR6","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/ana.26858","volume":"95","author":"A Duchow","year":"2024","unstructured":"Duchow, A., Bellmann-Strobl, J., Friede, T., Aktas, O., Angstwurm, K., Ayzenberg, I., et al. (2024). Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD. Annals Of Neurology, 95(4), 720\u2013732. https:\/\/doi.org\/10.1002\/ana.26858","journal-title":"Annals Of Neurology"},{"issue":"7","key":"503_CR7","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","volume":"270","author":"S Jarius","year":"2023","unstructured":"Jarius, S., Aktas, O., Ayzenberg, I., Bellmann-Strobl, J., Berthele, A., Giglhuber, K., et al. (2023). Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. Journal Of Neurology, 270(7), 3341\u20133368. https:\/\/doi.org\/10.1007\/s00415-023-11634-0","journal-title":"Journal Of Neurology"},{"key":"503_CR8","doi-asserted-by":"publisher","unstructured":"Tkachenko, D., Ayzenberg, I., Schoppe, L. M., Schulke, R., Paul, F., Duchow, A., et al. (2026). Socioeconomic impact of depression and pain in patients with neuromyelitis optica spectrum disorders. Neurol Res Pract, 8(1). https:\/\/doi.org\/10.1186\/s42466-026-00486-4","DOI":"10.1186\/s42466-026-00486-4"},{"issue":"2","key":"503_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/wnl.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., et al. (2015). International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85(2), 177\u2013189. https:\/\/doi.org\/10.1212\/wnl.0000000000001729","journal-title":"Neurology"},{"key":"503_CR10","doi-asserted-by":"publisher","first-page":"1515481","DOI":"10.3389\/fimmu.2024.1515481","volume":"15","author":"E Carnero Contentti","year":"2024","unstructured":"Carnero Contentti, E., Rojas, J. I., Alonso, R., Yeaman, M. R., & Weinshenker, B. G. (2024). Application and interpretation of core elements of the 2015 NMOSD diagnostic criteria in routine clinical practice. Frontiers In Immunology, 15, 1515481. https:\/\/doi.org\/10.3389\/fimmu.2024.1515481","journal-title":"Frontiers In Immunology"},{"issue":"12","key":"503_CR11","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1007\/s00415-020-10024-0","volume":"267","author":"M Gastaldi","year":"2020","unstructured":"Gastaldi, M., Scaranzin, S., Jarius, S., Wildeman, B., Zardini, E., Mallucci, G., et al. (2020). Cell-based assays for the detection of MOG antibodies: a comparative study. Journal Of Neurology, 267(12), 3555\u20133564. https:\/\/doi.org\/10.1007\/s00415-020-10024-0","journal-title":"Journal Of Neurology"},{"issue":"3","key":"503_CR12","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/acn3.52310","volume":"12","author":"Y Said","year":"2025","unstructured":"Said, Y., Filippatou, A., Tran, C., Rezavi, L., Guo, K., Smith, M. D., et al. (2025). Real-world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell-based assay. Annals Of Clinical And Translational Neurology, 12(3), 556\u2013564. https:\/\/doi.org\/10.1002\/acn3.52310","journal-title":"Annals Of Clinical And Translational Neurology"},{"issue":"4","key":"503_CR13","doi-asserted-by":"publisher","first-page":"205521732110526","DOI":"10.1177\/20552173211052656","volume":"7","author":"V Redenbaugh","year":"2021","unstructured":"Redenbaugh, V., Montalvo, M., Sechi, E., Buciuc, M., Fryer, J. P., McKeon, A., et al. (2021). Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin, 7(4), 20552173211052656. https:\/\/doi.org\/10.1177\/20552173211052656","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"9","key":"503_CR14","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","volume":"87","author":"P Waters","year":"2016","unstructured":"Waters, P., Reindl, M., Saiz, A., Schanda, K., Tuller, F., Kral, V., et al. (2016). Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. Journal of neurology neurosurgery and psychiatry, 87(9), 1005\u20131015. https:\/\/doi.org\/10.1136\/jnnp-2015-312601","journal-title":"Journal of neurology neurosurgery and psychiatry"},{"key":"503_CR15","doi-asserted-by":"publisher","unstructured":"Reindl, M., Schanda, K., Woodhall, M., Tea, F., Ramanathan, S., Sagen, J., et al. (2020). International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm, 7(2). https:\/\/doi.org\/10.1212\/nxi.0000000000000674","DOI":"10.1212\/nxi.0000000000000674"},{"issue":"10206","key":"503_CR16","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/s0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., et al. (2019). Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. The Lancet, 394(10206), 1352\u20131363. https:\/\/doi.org\/10.1016\/s0140-6736(19)31817-3","journal-title":"The Lancet"},{"issue":"6","key":"503_CR17","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","volume":"93","author":"SJ Pittock","year":"2023","unstructured":"Pittock, S. J., Barnett, M., Bennett, J. L., Berthele, A., de Seze, J., Levy, M., et al. (2023). Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. Annals Of Neurology, 93(6), 1053\u20131068. https:\/\/doi.org\/10.1002\/ana.26626","journal-title":"Annals Of Neurology"},{"issue":"7","key":"503_CR18","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock, S. J., Berthele, A., Fujihara, K., Kim, H. J., Levy, M., Palace, J., et al. (2019). Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. New England Journal Of Medicine, 381(7), 614\u2013625. https:\/\/doi.org\/10.1056\/NEJMoa1900866","journal-title":"New England Journal Of Medicine"},{"issue":"5","key":"503_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/s1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee, A., Greenberg, B. M., Bennett, J. L., Szczechowski, L., Fox, E., Shkrobot, S., et al. (2020). Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. The Lancet Neurology, 19(5), 402\u2013412. https:\/\/doi.org\/10.1016\/s1474-4422(20)30078-8","journal-title":"The Lancet Neurology"},{"issue":"22","key":"503_CR20","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura, T., Kleiter, I., Fujihara, K., Palace, J., Greenberg, B., Zakrzewska-Pniewska, B., et al. (2019). Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. New England Journal Of Medicine, 381(22), 2114\u20132124. https:\/\/doi.org\/10.1056\/NEJMoa1901747","journal-title":"New England Journal Of Medicine"},{"key":"503_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11910-z","author":"T K\u00fcmpfel","year":"2023","unstructured":"K\u00fcmpfel, T., Giglhuber, K., Aktas, O., Ayzenberg, I., Bellmann-Strobl, J., Haussler, V., et al. (2023). Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. Journal Of Neurology. https:\/\/doi.org\/10.1007\/s00415-023-11910-z","journal-title":"Journal Of Neurology"},{"key":"503_CR22","doi-asserted-by":"publisher","unstructured":"St\u00f6gbauer, J., Schegerer, V., Klein, C., Pawlitzki, M., Meuth, S. G., Aktas, O., et al. (2025). Therapeutic approaches in adults with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A review of current evidence. Autoimmun Rev, 103970. https:\/\/doi.org\/10.1016\/j.autrev.2025.103970","DOI":"10.1016\/j.autrev.2025.103970"},{"key":"503_CR23","doi-asserted-by":"publisher","first-page":"101488","DOI":"10.1016\/j.msard.2019.101488","volume":"37","author":"S Gmuca","year":"2020","unstructured":"Gmuca, S., Hardy, D. I., Narula, S., Stoll, S., Harris, J., Zhao, Y., et al. (2020). Validation of claims-based diagnoses of adult and pediatric neuromyelitis optica spectrum disorder and variations in diagnostic evaluation and treatment initiation. Mult Scler Relat Disord, 37, 101488. https:\/\/doi.org\/10.1016\/j.msard.2019.101488","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"503_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40120-021-00311-x","volume":"11","author":"RK Knapp","year":"2022","unstructured":"Knapp, R. K., Hardtstock, F., Wilke, T., Maywald, U., Deiters, B., Schneider, S., et al. (2022). Evaluating the Economic Burden of Relapses in Neuromyelitis Optica Spectrum Disorder: A Real-World Analysis Using German Claims Data. Neurol Ther, 11(1), 247\u2013263. https:\/\/doi.org\/10.1007\/s40120-021-00311-x","journal-title":"Neurol Ther"},{"key":"503_CR25","unstructured":"LamaPoll [Internet] Berlin: LamaPoll; \u00a9 2007\u20132026. Accessed 15 January 2025. https:\/\/www.lamapoll.de"},{"key":"503_CR26","unstructured":"German Neurological Society. Accessed 15 December 2025. https:\/\/www.dgn.org"},{"key":"503_CR27","unstructured":"National Association of Statutory Health Insurance Physicians - Facts and Figures. Accessed 15 December 2025. https:\/\/www.kbv.de\/infothek\/zahlen-und-fakten"},{"key":"503_CR28","unstructured":"German Medical Association. Statistics on Doctors as of 31 December 2025. Accessed 01 May 2026. https:\/\/www.bundesaerztekammer.de\/fileadmin\/user_upload\/BAEK\/Ueber_uns\/Statistik\/AErztestatistik_2025.pdf"},{"issue":"2","key":"503_CR29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1212\/wnl.0000000000001749","volume":"85","author":"I Kister","year":"2015","unstructured":"Kister, I., & Paul, F. (2015). Pushing the boundaries of neuromyelitis optica: does antibody make the disease? Neurology, 85(2), 118\u2013119. https:\/\/doi.org\/10.1212\/wnl.0000000000001749","journal-title":"Neurology"},{"issue":"11","key":"503_CR30","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","volume":"73","author":"V Damato","year":"2016","unstructured":"Damato, V., Evoli, A., & Iorio, R. (2016). Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis. JAMA Neurol, 73(11), 1342\u20131348. https:\/\/doi.org\/10.1001\/jamaneurol.2016.1637","journal-title":"JAMA Neurol"},{"issue":"36","key":"503_CR31","doi-asserted-by":"publisher","first-page":"e30347","DOI":"10.1097\/md.0000000000030347","volume":"101","author":"GY Dong","year":"2022","unstructured":"Dong, G. Y., Meng, Y. H., & Xiao, X. J. (2022). A meta-analysis on efficacy and safety of rituximab for neuromyelitis optica spectrum disorders. Medicine (Baltimore), 101(36), e30347. https:\/\/doi.org\/10.1097\/md.0000000000030347","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"503_CR32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/jnnp-2024-334764","volume":"96","author":"V Haussler","year":"2025","unstructured":"Haussler, V., Trebst, C., Engels, D., Pellkofer, H., Havla, J., Duchow, A., et al. (2025). Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD. Journal of neurology neurosurgery and psychiatry, 96(6), 582\u2013592. https:\/\/doi.org\/10.1136\/jnnp-2024-334764","journal-title":"Journal of neurology neurosurgery and psychiatry"},{"issue":"8","key":"503_CR33","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","volume":"88","author":"JP Stellmann","year":"2017","unstructured":"Stellmann, J. P., Krumbholz, M., Friede, T., Gahlen, A., Borisow, N., Fischer, K., et al. (2017). Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. Journal of neurology neurosurgery and psychiatry, 88(8), 639\u2013647. https:\/\/doi.org\/10.1136\/jnnp-2017-315603","journal-title":"Journal of neurology neurosurgery and psychiatry"},{"issue":"10","key":"503_CR34","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","volume":"262","author":"H Z\u00e9phir","year":"2015","unstructured":"Z\u00e9phir, H., Bernard-Valnet, R., Lebrun, C., Outteryck, O., Audoin, B., Bourre, B., et al. (2015). Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. Journal Of Neurology, 262(10), 2329\u20132335. https:\/\/doi.org\/10.1007\/s00415-015-7852-y","journal-title":"Journal Of Neurology"},{"issue":"3","key":"503_CR35","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/13524585241226830","volume":"30","author":"PA Bilodeau","year":"2024","unstructured":"Bilodeau, P. A., Vishnevetsky, A., Molazadeh, N., Lotan, I., Anderson, M., Romanow, G., et al. (2024). Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. Multiple sclerosis (Houndmills Basingstoke England), 30(3), 357\u2013368. https:\/\/doi.org\/10.1177\/13524585241226830","journal-title":"Multiple sclerosis (Houndmills Basingstoke England)"},{"key":"503_CR36","doi-asserted-by":"publisher","first-page":"578686","DOI":"10.1016\/j.jneuroim.2025.578686","volume":"407","author":"S \u015een","year":"2025","unstructured":"\u015een, S., K\u00fcrt\u00fcnc\u00fc, M., Demir, S., G\u00fcnd\u00fcz, T., Demirel, E., T\u00fct\u00fcnc\u00fc, M., et al. (2025). Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD). Journal Of Neuroimmunology, 407, 578686. https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578686","journal-title":"Journal Of Neuroimmunology"},{"key":"503_CR37","doi-asserted-by":"crossref","unstructured":"Levy, M., Flanagan, E. P., K\u00fcmpfel, T., Marignier, R., Fujihara, K., Hemingway, C. (2026). Safety and efficacy of satralizumab in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Results from the phase 3 METEOROID trial. 78th Annual Meeting of the AAN 2026, Chicago, IL, USA (Hybrid); April 18\u201322, 2026.","DOI":"10.1212\/WNL.0000000000217915"},{"key":"503_CR38","unstructured":"cosMOG trial. Accessed 10 May 2026. https:\/\/clinicaltrials.gov\/study\/NCT05063162"},{"key":"503_CR39","doi-asserted-by":"publisher","unstructured":"Linse, K., Lule, D., Schoberl, F., Reilich, P., Ilse, B., Metelmann, M., et al. (2026). Between guidelines and reality: expert neurologists\u2019 perspectives on structural resources for ALS care in Germany. Neurol Res Pract, 8(1). https:\/\/doi.org\/10.1186\/s42466-026-00481-9","DOI":"10.1186\/s42466-026-00481-9"},{"issue":"1","key":"503_CR40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s42466-024-00333-4","volume":"6","author":"I Voigt","year":"2024","unstructured":"Voigt, I., Akgun, K., Inojosa, H., Haas, J., Temmes, H., Meuth, S. G., et al. (2024). MS brain health quality standards: a survey on the reality in clinical practice in Germany. Neurol Res Pract, 6(1), 59. https:\/\/doi.org\/10.1186\/s42466-024-00333-4","journal-title":"Neurol Res Pract"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-026-00503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-026-00503-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-026-00503-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:02:23Z","timestamp":1781884943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42466-026-00503-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["503"],"URL":"https:\/\/doi.org\/10.1186\/s42466-026-00503-6","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The survey was done within the framework of the project \u201cNUTSEN: New therapies for rare diseases like NMOSD\u201d, which has been approved by the Ethics Committee of the Technical University of Munich, Germany (Reference 2024-599-S-NP). The survey design did not necessitate informed consent procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KG is receiving funding from an ECTRIMS-MAGNIMS fellowship, outside the present work. She has received reimbursement of travelling expenses from UCB, Nexstim and Viatris. She has received personal fees for advisory boards from Viatris.AlB has nothing to declare.CZ received reimbursement of travelling expenses from UCB.IK has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, Biogen, GlaxoSmithKline, Hexal, Juvis\u00e9 Pharmaceuticals, Merck, Neuraxpharm, Roche\/Chugai, Sanofi, and Viatris.IA received research grants, speaking honoraria and travel support from Argenx, Alexion, Amgen, Roche, Sanofi and Merck.AcB receives funding from the Innovationsausschuss of the German Federal Joint Committee (G-BA; grant 01VSF23040) and from the German Federal Ministry of Research, Technology and Space (BMFTR; grant 01ZZ2505A). He has received consulting and\/or speaker fees from Alexion, Argenx, Biogen, CSL Behring, Horizon\/Amgen, Merck, Neuraxpharm, Novartis, and Roche, and his institution has received compensation for clinical trials from Ad Scientiam, Alexion, Biogen, Merck, Novartis, Roche, and Sanofi Genzyme.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}